Compare ASTS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTS | JAZZ |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 16.1B |
| IPO Year | 2019 | 2007 |
| Metric | ASTS | JAZZ |
|---|---|---|
| Price | $62.49 | $259.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $72.10 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 10.3M | 699.7K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.17 |
| Revenue | $4,400,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $167.10 | $6.22 |
| Revenue Next Year | $391.80 | $7.68 |
| P/E Ratio | ★ N/A | $35.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.50 | $123.89 |
| 52 Week High | $133.86 | $265.05 |
| Indicator | ASTS | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 57.47 |
| Support Level | $51.81 | $240.63 |
| Resistance Level | $92.38 | $265.05 |
| Average True Range (ATR) | 4.19 | 6.32 |
| MACD | -0.24 | -0.20 |
| Stochastic Oscillator | 3.76 | 67.80 |
AST SpaceMobile Inc is currently designing, developing and manufacturing the constellation of BlueBird (BB) satellites and has begun launching its planned space-based Cellular Broadband network distributed through a constellation of low Earth orbit (LEO) satellites. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.